Encyclopaedia - Finance

People spend a lot of time and effort trying to steer clear of certain things: traffic, bad movies, and sub-par restaurants com

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

e to mind. But none of these experiences, no matter how unpleasant, can be as expensive as a bad mutual fund investment. They m

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

st be avoided at all costs!

The good news is that there are solid, common sense strategies that you can put in place

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

right now to avoid bad mutual fund investments. The key is to pay attention and be objective as you evaluate your funds. Follo

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

these four simple concepts for establishing and upgrading your mutual fund portfolio, and you should see your investment perfo

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

rmance improve significantly over time.

Start With a Solid Asset Allocation Plan
Perhaps the most import

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

nt factor in avoiding bad mutual fund investments is to select the right asset classes for current market conditions. In most c

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

ases, a diversified portfolio including domestic stock, international stock, bond, specialty, and money market funds is appropr

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ate. But how much do you allocate to each asset class? That's the key question, and professional help in this area probably mak

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

es sense.

Pay Attention to Momentum
Buying a mutual fund and holding it through thick and thin is a sure

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

recipe for underperformance. If you truly want to avoid bad mutual fund investments, you have to be ready to upgrade your holdi

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

gs to funds that are gaining momentum under current market conditions. Remember, sometimes selling a bad mutual fund can be a m

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ore important factor to your performance than buying a good one.

Don't Be Shackled by Psychological Handcuffs

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

br> If it's time to sell and upgrade from a mutual fund that's lagging, do it! Don't hold a fund too long simply because it's

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

one of your "favorites" or it has a short-term redemption fee. The investment merits of the switch almost always outweigh these

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

factors, including any 1.5% or 2% fee. Of course, be reasonable. If you are within a few days of the expiration of the fee peri

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

od, you may want to wait. But if it's a month or more, pull the trigger.

Don't Buy Long-Term Performers Blindly<

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

b>
There are plenty of funds out there with good long-term track records that lag the leaders for long periods. It doesn't

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

mean they are bad mutual funds investments, but that there are other funds better suited to current market conditions. You can

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

do better! Take the time to see which funds are hot--and which are not. It can make a huge difference in your long-term returns

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Encyclopaedia - How to Avoid Bad Mutual Fund Investments

Related Articles: